公开(公告)号：US20150118241A1

公开(公告)日：2015-04-30

申请号：US14401002

申请日：2013-05-14

Applicant: Biogen Idec MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky

IPC: C07K16/28 ,  C07K14/47

CPC classification number: C07K16/2803 ,  C07K14/4705 ,  C07K14/70503 ,  C07K2317/76 ,  C07K2319/30

Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.

Abstract translation: 本发明提供了通过施用LINGO-2拮抗剂治疗涉及运动神经元存活和轴突生长的疾病，病症或损伤的方法，包括肌营养侧索硬化。 一种用于促进运动神经元存活的示例性方法，包括使所述运动神经元与有效量的包含LINGO-2拮抗剂的组合物接触，所述组合物选自：（i）可溶性LINGO-2多肽; （ii）LINGO-2抗体或其抗原结合片段; （iii）LINGO-2拮抗剂多核苷酸; （iv）LINGO-2适体; 和（v）两种或更多种所述LINGO-2拮抗剂的组合。

公开(公告)号：US20150110792A1

公开(公告)日：2015-04-23

申请号：US14359784

申请日：2012-11-16

Applicant: Biogen Idec MA Inc. ,  University of Iowa Research Foundation

Inventor： Veronique Bailly ,  Ellen Garber ,  Paul D. Rennert ,  Nicholas Joseph Lennemann ,  Wendy Jean Maury ,  Sven Henrik Moller-Tank

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.

Abstract translation: 公开了在蛋白质的BED面上结合人TIM-1的抗体和抗体片段。 还公开了使用抗体和抗体片段抑制或降低TIM-1与磷脂酰丝氨酸结合，抑制或降低TIM-1与树突状细胞的结合以及治疗或预防免疫学疾病如炎性和自身免疫病症的方法。

公开(公告)号：US20150057608A1

公开(公告)日：2015-02-26

申请号：US14387939

申请日：2013-03-28

Applicant: Biogen Idec MA Inc.

Inventor： Carl F. Hitscherich, JR. ,  Soham Bhatt ,  Nam Chen ,  Chase Fetzer

IPC: A61M5/31 ,  A61M5/19 ,  A61M5/00 ,  A61M5/315

CPC classification number: A61M5/3137 ,  A61M5/002 ,  A61M5/19 ,  A61M5/284 ,  A61M5/31511 ,  A61M5/347 ,  A61M5/502 ,  A61M2005/1787 ,  A61M2005/3139 ,  A61M2005/31516 ,  A61M2202/0452 ,  A61M2205/584 ,  A61M2205/586 ,  A61M2209/06

Abstract: Delivery devices and components thereof are disclosed. In an embodiment, a delivery device may include a barrel holding a liquid for delivery. The delivery device may also include a finger flange assembly coupled to the barrel. The finger flange assembly may include a first flange and a second flange each extending laterally from opposite sides of the finger flange assembly, wherein the first flange and the second flange each curve toward the barrel. The delivery device may also include a plunger coupled to the barrel and passing through the finger flange assembly. The plunger may also include a disc-shaped head.

Abstract translation: 公开了输送装置及其部件。 在一个实施例中，输送装置可以包括保持用于输送的液体的桶。 递送装置还可以包括联接到筒的指状凸缘组件。 指状凸缘组件可以包括第一凸缘和第二凸缘，每个第一凸缘和第二凸缘均从指状凸缘组件的相对侧横向延伸，其中第一凸缘和第二凸缘均朝向圆筒弯曲。 输送装置还可以包括联接到筒体并穿过指状凸缘组件的柱塞。 柱塞还可以包括盘形头部。

公开(公告)号：US08932821B2

公开(公告)日：2015-01-13

申请号：US13827771

申请日：2013-03-14

Applicant: Biogen Idec MA Inc.

Inventor： Sha Mi ,  John McCoy ,  R. Blake Pepinsky ,  Daniel H. S. Lee

IPC: G01N33/53 ,  G01N33/50 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  G01N33/68 ,  A61K38/00

CPC classification number: G01N33/56966 ,  A61K38/00 ,  C07K14/4702 ,  C07K14/70571 ,  C07K16/18 ,  C07K16/2803 ,  C07K2319/30 ,  C12N5/0619 ,  C12N2500/46 ,  G01N33/5058 ,  G01N33/6896

Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

Abstract translation: 本发明提供了Sp35多肽及其融合蛋白，Sp35抗体及其抗原结合片段和编码其的核酸。 本发明还提供了包含此类Sp35抗体，其抗原结合片段，Sp35多肽及其融合蛋白的制备和使用方法。

公开(公告)号：US08894999B2

公开(公告)日：2014-11-25

申请号：US13936084

申请日：2013-07-05

Applicant: Biogen Idec MA Inc.

Inventor： Sha Mi ,  Kenneth J. Rhodes ,  R. Blake Pepinsky

IPC: A61K39/395 ,  A61K39/00 ,  A61K38/00 ,  C07K14/00 ,  C12N15/113 ,  A61K31/713 ,  A61K38/17 ,  C07K16/28 ,  C12N15/11 ,  A61K31/7088 ,  C07K14/705

CPC classification number: C07K16/2878 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K38/177 ,  A61K39/39541 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/70578 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的死亡受体-6（DR6）蛋白，现在已被证明对调节神经系统细胞凋亡是重要的。 此外，已经发现p75是DR6的配体。 因此，本发明涉及使用DR6和/或p75拮抗剂抑制DR6和p75相互作用的方法。 此外，本文所述的方法包括使用DR6拮抗剂（任选与p75拮抗剂组合）促进神经系统细胞存活的方法，以及任选地与p75拮抗剂组合施用DR6拮抗剂治疗神经变性病症的方法 。

公开(公告)号：US20140308280A1

公开(公告)日：2014-10-16

申请号：US14213180

申请日：2014-03-14

Applicant: Biogen Idec MA Inc.

Inventor： Kevin MALONEY ,  Daniel Gage ,  Ahmad Abdul-Fattah

IPC: A61K38/37 ,  C07K14/755 ,  C07K16/28

CPC classification number: A61K38/37 ,  C07K14/755 ,  C07K16/2833 ,  C07K2319/30

Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.

Abstract translation: 本发明提供因子VIII多肽例如FVIII-Fc的制剂及其使用方法。 FVIII多肽可以是重组FVIII蛋白，短效FVIII蛋白或长效FVIII蛋白。 包含FVIII多肽的药物制剂可用于个体预防，每周预防，情景（按需）治疗或血友病围手术期管理。

公开(公告)号：US20140234299A1

公开(公告)日：2014-08-21

申请号：US14158764

申请日：2014-01-17

Applicant: Imperial College of Science, Technology and Medicine ,  Biogen Idec MA Inc.

Inventor： Roy Lobb ,  Charles Pusey ,  Andrew Allen

IPC: C07K16/28 ,  A61K31/702 ,  A61K38/08

CPC classification number: C07K16/2842 ,  A61K31/702 ,  A61K38/08 ,  A61K2039/505 ,  C07K2319/00 ,  C07K2319/30

Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists.

Abstract translation: 本发明提供用于治疗患有慢性肾功能衰竭或处于慢性肾功能衰竭风险的哺乳动物受试者或用于治疗需要肾替代治疗的风险的药物的方法。 该方法涉及给予某些整合素拮抗剂。

公开(公告)号：US20140194427A1

公开(公告)日：2014-07-10

申请号：US14201380

申请日：2014-03-07

Applicant: Biogen IDEC MA Inc.

Inventor： Jianhua CHAO

IPC: C07C69/60 ,  A61K31/235 ,  A61K31/24 ,  A61K45/06 ,  C07D295/145 ,  C07C229/36 ,  C07C69/76 ,  A61K31/5375 ,  A61K31/225

CPC classification number: C07C69/60 ,  A61K31/225 ,  A61K31/235 ,  A61K31/24 ,  A61K31/5375 ,  A61K45/06 ,  C07B59/001 ,  C07C69/533 ,  C07C69/76 ,  C07C229/36 ,  C07D295/145

Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.

Abstract translation: 提供式（I）的化合物或其药学上可接受的盐。 还提供了治疗，预防或改善疾病的方法，包括向需要治疗疾病的受试者施用有效量的本文所述的式（I）化合物。 在一个实施方案中，该方法是神经变性疾病，例如多发性硬化，肌萎缩性侧索硬化，帕金森病，亨廷顿病或阿尔茨海默氏病。

公开(公告)号：US20140179779A1

公开(公告)日：2014-06-26

申请号：US14136990

申请日：2013-12-20

Applicant: Biogen IDEC MA Inc.

Inventor： Jianhua CHAO

IPC: C07C69/60 ,  C07C69/533

CPC classification number: C07C69/60 ,  A61K31/225 ,  A61K31/235 ,  A61K31/24 ,  A61K31/5375 ,  A61K45/06 ,  C07B59/001 ,  C07C69/533 ,  C07C69/76 ,  C07C229/36 ,  C07D295/145

Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of activating the Nrf2 pathway, comprising contacting cells with a sufficient amount of a compound of formula (I) described herein. Also provided is a method of treating a neurodegenerative disease, comprising administering to a subject in need of treatment for the neurodegenerative disease an effective amount of a compound of formula (I) described herein.

Abstract translation: 提供式（I）的化合物或其药学上可接受的盐。 还提供了激活Nrf2途径的方法，包括使细胞与足量的本文所述的式（I）化合物接触。 还提供了一种治疗神经变性疾病的方法，包括向需要治疗神经变性疾病的受试者施用有效量的本文所述的式（I）化合物。

公开(公告)号：US20140067308A1

公开(公告)日：2014-03-06

申请号：US14041318

申请日：2013-09-30

Applicant: Biogen Idec MA Inc.

Inventor： Paul CUNNIEN ,  Joydeep GANGULY ,  Basav GHOSH ,  Asif LADIWALA ,  Robert SONG ,  Jorg THOMMES

IPC: G01N33/00

CPC classification number: G01N33/00 ,  G01N30/34 ,  G01N30/8617 ,  G01N30/8693 ,  G01N30/88 ,  G01N2030/562 ,  G01N2030/889

Abstract: The present invention provides automated systems and methods for monitoring column performance in process chromatography, and applications thereof. In an embodiment, column performance is monitored by generating a plurality of process values such as, for example, conductivity values or pH values with a detector during a chromatography step transition between a first mobile phase liquid and a second mobile phase liquid. The process values are transformed to form transformed process values in which noise present in the process values is suppressed. Column performance parameters are calculated based on the transformed process values and displayed during movement of the second mobile phase liquid through the chromatography column. The displayed performance parameters enable an operator to make a determination, for example, regarding the quality of the chromatography column packing and whether to continue the chromatography process or stop the chromatography process until the chromatography column can be repacked or replaced.

Abstract translation: 本发明提供了用于监测过程色谱中色谱柱性能的自动化系统和方法及其应用。 在一个实施方案中，通过在第一流动相液体和第二流动相液体之间的色谱步骤过渡期间通过产生多个过程值，例如电导率值或pH值来监测色谱柱性能。 过程值被转换以形成其中抑制存在于过程值中的噪声的变换过程值。 色谱柱性能参数是基于转化过程值计算的，并在第二流动相液体通过色谱柱移动期间显示。 显示的性能参数使得操作者能够例如关于色谱柱填充的质量以及是否继续色谱法或停止色谱法以确定色谱柱可以重新包装或更换。